<strong>CIT</strong>2011www.citmd.comEXHIBITORS' DIRECTORYand industrialization of biochip technology, is registered asan innovative high-tech enterprise. Accompanied by the firstindividual drug detection product appearing on market in2005 approved by U.S. FDA, BaiO immediately developedmicroarray detection kits and automated detection systems forpersonal medicine scheme, and officially owned completelyindependent intellectual property rights. The products newlydevelopedby BaiO were approved by SFDA and sold indomestic and oversea markets preceding its competitors.BaiO will be dedicated to deliver high-grade medical microarraySanofi-Aventis(China) Investment Co.,Ltd赛 诺 菲 安 万 特 ( 中 国 ) 投 资 有 限 公 司Booth Number / 展 位 号 : A45Address: Floor31 office bldg.,Plaza66,Nanjing Rd.West,Shanghai地 址 : 上 海 市 南 京 西 路 1266 号 恒 隆 广 场 31 楼电 话 : 021-6288 1616传 真 : 021-6288 2335Email: Dong.Wei@sanofi-aventis.comSanofi-aventis is one of the first foreign pharmaceuticalcompanies to open offices in China. It is also one of the fastestgrowing healthcare companies in China, with leading productscovering vaccines and major therapeutic areas, includingcardiovascular/thrombosis, diabetes, oncology, internalmedicine, and central nervous system. Sanofi-aventis currentlyemploys 3,700 people in 200 cities across China.Sanofi-aventis has three manufacturing sites in Beijing,Hangzhou and Shenzhen. The Beijing plant is located at BeijingEconomic & Technology Development Area. It produces solidformulations and repacks injectables, and its portfolio includesAmaryl ® (Diabetes), Tritace ® (Hypertension), and Essentiale ®(Chronic Liver Disease). In April 2009, sanofi-aventis announcedan increase of investment in the amount of US$90 million (600million Renminbi) to extend its current manufacturing facilityin Beijing and to build pre-filled injection production lines forLantus ® (Insulin Glargine) SoloSTAR ® .Sanofi-aventis Hangzhou plant produces solid and oralformulations, and repacks injectables. Its product portfolioincludes Plavix ® , Aprovel ® , Co-Aprovel ® , Ticlid ® , Cordarone ® ,Digoxin (Cardiovascular); Stilnox ® , Depakine ® , Perenan ® (CentralNervous System); Eloxatin ® (Oncology); as well as Xatral ® , No-Spa ® , and Ranitidine (Internal Medicine). In April 2009, sanofiaventisannounced an investment of 410M Renminbi (44MEuro) to relocate its current manufacturing facility fromdowntown Hangzhou and build a new manufacturing site inBinjiang New Development Zone. The site is also expected toundertake an upgrade of technologies and equipment, andbecome an export hub to other Asian countries.Shenzhen Sanofi Pasteur Biological Products Co., Ltd. (SSPBP)was established in Beijing in 1996. Sanofi Pasteur is a leaderof China’s fast growing private market. Its main productsinclude Vaxigrip ® , Act-Hib ® , Pneumo23 ® , Imovax Polio Vaccine,Verorab ® , and Meningo A+C ® .In November 2007, Sanofi Pasteur, the vaccines division ofsanofi-aventis Group, announced an investment of US$94million (700 million Renminbi) to build a hi-tech manufacturingfacility in Shenzhen to produce Vaxigrip ® for the prevention ofseasonal influenza and to contribute to pandemic readinessin China. The new facility is scheduled to begin production in2012, and the initial planned capacity is 25 million doses ofseasonal influenza vaccine. The facility is built according tospecifications allowing Sanofi Pasteur to switch to pandemicvaccine manufacturing if an influenza pandemic is declaredand once a pandemic influenza strain is identified by the WorldHealth Organization (WHO).In October 2008, sanofi-aventis strengthened its R&D presencein China with the expansion of its R&D facility in Shanghai, thenew establishment of a state-of-the-art Biometrics Center inBeijing, and the signature of a partnership agreement withthe Shanghai Institutes for Biological Sciences (SIBS) for thediscovery of breakthrough drugs for neurological diseases,diabetes, and cancer.In October 2009, Merial, the Animal Health division of sanofiaventis,announced an investment of over 70 million USD toexpand its facility in Nanchang, Jiangxi Province. The facilityproduces poultry vaccines for the domestic Chinese market.Merial Animal Health Co. (China) has been in operation foralmost 20 years.In January 2010, Sanofi-aventis signed agreements withHangzhou Minsheng Pharmaceutical Co., Ltd to form anew consumer healthcare joint venture. Subject to certainconditions precedent and regulatory approvals, sanofi-aventisis to obtain a majority equity stake in the new venture.135
<strong>CIT</strong>2011www.citmd.comEXHIBITORS' DIRECTORYShanghai Bracco Sine Pharmaceutical Corp. Ltd.上 海 博 莱 科 信 谊 药 业 有 限 责 任 公 司Booth Number / 展 位 号 : A48Address: Rm.610-612 Gangtai Plaza No.700 Yan An East Road,Shanghai China地 址 : 中 国 上 海 延 安 东 路 700 号 港 泰 广 场 610-612 室电 话 : +86-21-5385 1100传 真 : +86-21-5385 1020Email: roy.yang@braccosine.comBracco is an international group active in the Healthcaresector through Bracco Imaging (diagnostic imaging),Pharma (prescription and over the counter drugs), Acist(advanced injection systems based in Minneapolis), andthe Centro Diagnostico Italiano (diagnostic clinic) in Milan.The Group operates in over 80 countries around theworld and employs about 2,300 people. Bracco reportedconsolidated revenues of approximately 900 million euro,of which about 60% coming from international sales.Through the Bracco Imaging subsidiary, th e Group is oneof the World’s leading companies in the diagnosticimaging business, where it develops imaging agents andsolutions for all key diagnostic imaging modalities (X-Ray,Magnetic Resonance, Ultrasound, and Nuclear Medicine).Originally established as a pharmaceuticals Company in1927, over the years Bracco has intensified its commitment toinnovative specialist research in imaging agents for diagnosticmedicine. A key breakthrough came in the 1970s with thedevelopment of the iopamidol molecule, the first ready-tousenon-ionic contrast agent. In the wake of this success,at the end of the 1980s the Group launched a program forinternational expansion, notably in the USA, now BraccoImaging’s primary market. Here, the Group operatesthrough Bracco Diagnostics Inc. and Bracco Research USA,both based in Princeton, New Jersey, where its worldwideclinical development work is coordinated. Bracco has alsoestablished itself as a major player in Japan, Europe and China,where it has the sales head quarters and the manufacturingsite in Shanghai and a Representative Office for regulatoryand clinical development in Beijing Today Bracco Imaging,headquartered in Milan, operates in over 80 marketsworldwide, either directly or indirectly, through subsidiaries,joint ventures, licenses and distribution par tnershipagreements. It employs more than 1,400 persons, includingmore than 300 R&D and medical & regulatory affairs specialists.Bracco R&D Centers are located in the Bioindustry Parkof Colleretto Giacosa (Turin, Italy), in the high technologyarea of Plan-les-Ouates (Geneva, Switzerland) and inthe biotech/academy town of Princeton (New Jersey,USA), e a c h of t hem s p e c ialized in a d iffe re nt a re a .Bracco has a high-profile international research network inthe imaging agents field, where its products are regarded asgold standards for the key diagnostic imaging modalities.The network develops new products for the sophisticatedrequirements of the latest diagnostic procedures, such asmagnetic resonance and ultrasound, and is supported bycooperation agreements with Italian and international publicand private research bodies, clinics and universities. TheCompany invests approximately 11% of reference turnover inits R&D work every year and has a portfolio comprising over1,500 patents.Lake Region Medical雷 科 医 疗Booth Number / 展 位 号 : A50/A51Address: 340 Lake Hazeltine Drive, Chaska, MN 55318-1029 USA电 话 : 952.361.2506传 真 : 952.448.7012Email: jsauter@lakergn.comLake Region Medical is a global leader in OEM devices,specializing in minimally-invasive technologies, such asguidewires. With extensive industry knowledge, technicalexpertise and p ortfolio of patented technologies, Lake Regionis dedicated to the development of innovative productsfor minimally-invasive therapies for cardiovascular, cardiacrhythm management, neurovascular and peripheral vascularapplications.Kinhely (Shenzhen) Bio-tech Co.,Ltd深 圳 市 金 瑞 凯 利 生 物 科 技 有 限 公 司Booth Number / 展 位 号 : A67/A68Address: Room 1007, No.18 Gufang Road, Shanghai地 址 : 上 海 古 方 路 18 号 1007 室电 话 : 021-6413 6730传 真 : 021-6413 6370Email: Crystalfu0917@yahoo.com.cn深 圳 市 金 瑞 凯 利 生 物 科 技 有 限 公 司 , 于 2007 年 初 正 式 成 立 ,是 一 个 专 门 从 事 心 脏 介 入 医 疗 产 品 的 研 制 和 开 发 及 生 产 和 服务 的 公 司 , 公 司 生 产 基 地 设 在 深 圳 市 福 田 区 彩 电 工 业 园 区内 。 公 司 研 发 的 海 利 欧 斯 (Helioos) 药 物 支 架 系 统 已 通 过 注 册型 式 检 验 和 动 物 实 验 , 已 完 成 了 国 内 首 个 医 疗 器 械 随 机 单 盲平 行 对 照 临 床 验 证 试 验 。 目 前 从 几 个 临 床 试 验 中 心 的 专 家 、患 者 及 初 步 临 床 的 结 果 以 及 我 们 的 临 床 试 验 数 据 方 面 获 得 的信 息 , 均 认 为 产 品 已 可 与 世 界 已 上 市 最 好 的 产 品 比 美 , 甚 至在 疗 效 上 更 有 特 点 。136
- Page 9 and 10:
CIT2011www.citmd.comWelcome Message
- Page 11 and 12:
CIT2011www.citmd.comOrganizationLuy
- Page 13 and 14:
CIT2011www.citmd.comOrganizationSid
- Page 15 and 16:
CIT2011www.citmd.comOrganizationChi
- Page 17 and 18:
CIT2011www.citmd.comOrganizationShe
- Page 19:
CIT2011www.citmd.comOrganizationSha
- Page 22 and 23:
CIT2011www.citmd.comPROGRAM AT A GL
- Page 24 and 25:
www.citmd.comCIT2011 www.citmd.comW
- Page 26 and 27:
CIT2011www.citmd.comWednesday, marc
- Page 28 and 29:
CIT2011www.citmd.comWednesday, marc
- Page 30 and 31:
CIT2011www.citmd.comWednesday, marc
- Page 32 and 33:
CIT2011www.citmd.comWednesday, marc
- Page 34 and 35:
CIT2011www.citmd.comThursday, March
- Page 36 and 37:
CIT2011www.citmd.comThursday, March
- Page 38 and 39:
CIT2011www.citmd.comThursday, March
- Page 40 and 41:
CIT2011www.citmd.comThursday, March
- Page 42 and 43:
CIT2011www.citmd.comThursday, March
- Page 44 and 45:
CIT2011www.citmd.comFriday, March 1
- Page 46 and 47:
CIT2011www.citmd.comFriday, March 1
- Page 48 and 49:
CIT2011www.citmd.comFriday, March 1
- Page 50 and 51:
CIT2011www.citmd.comFriday, March 1
- Page 52 and 53:
CIT2011www.citmd.comFriday, March 1
- Page 54 and 55:
CIT2011www.citmd.comFriday, March 1
- Page 56 and 57:
CIT2011www.citmd.comFriday, March 1
- Page 58 and 59:
CIT2011www.citmd.comSaturday, March
- Page 60 and 61:
CIT2011www.citmd.comSaturday, March
- Page 62 and 63:
CIT2011www.citmd.comSaturday, March
- Page 64 and 65:
CIT2011www.citmd.comSaturday, March
- Page 66 and 67:
CIT2011www.citmd.comSaturday, March
- Page 68 and 69:
CIT2011www.citmd.comSaturday, March
- Page 70 and 71:
CIT2011www.citmd.comE-POSTER PROGRA
- Page 72 and 73:
CIT2011www.citmd.comE-POSTER PROGRA
- Page 74 and 75:
CIT2011www.citmd.comE-POSTER PROGRA
- Page 76 and 77:
CIT2011www.citmd.com欢 迎 辞各
- Page 78 and 79:
CIT2011www.citmd.com大 会 组 织
- Page 80 and 81:
CIT2011www.citmd.com大 会 组 织
- Page 82 and 83:
CIT2011www.citmd.com大 会 组 织
- Page 84 and 85:
CIT2011www.citmd.com大 会 组 织
- Page 86 and 87:
CIT2011www.citmd.com会 议 信 息
- Page 88 and 89:
CIT2011www.citmd.com日 程 一 览
- Page 90 and 91:
www.citmd.comCIT2011 www.citmd.comW
- Page 92 and 93: CIT2011www.citmd.com2011 年 3 月
- Page 94 and 95: CIT2011www.citmd.com2011 年 3 月
- Page 96 and 97: CIT2011www.citmd.com2011 年 3 月
- Page 98 and 99: CIT2011www.citmd.com2011 年 3 月
- Page 100 and 101: CIT2011www.citmd.com2011 年 3 月
- Page 102 and 103: CIT2011www.citmd.com2011 年 3 月
- Page 104 and 105: CIT2011www.citmd.com2011 年 3 月
- Page 106 and 107: CIT2011www.citmd.com2011 年 3 月
- Page 108 and 109: CIT2011www.citmd.com2011 年 3 月
- Page 110 and 111: CIT2011www.citmd.com2011 年 3 月
- Page 112 and 113: CIT2011www.citmd.com2011 年 3 月
- Page 114 and 115: CIT2011www.citmd.com2011 年 3 月
- Page 116 and 117: CIT2011www.citmd.com2011 年 3 月
- Page 118 and 119: CIT2011www.citmd.com2011 年 3 月
- Page 120 and 121: CIT2011www.citmd.com2011 年 3 月
- Page 122 and 123: CIT2011www.citmd.com2011 年 3 月
- Page 124 and 125: CIT2011www.citmd.com2011 年 3 月
- Page 126 and 127: CIT2011www.citmd.com2011 年 3 月
- Page 129 and 130: CIT2011www.citmd.com2011 年 3 月
- Page 131 and 132: CIT2011www.citmd.comCIT Hands-on Ce
- Page 133 and 134: CIT2011www.citmd.comCIT Hands-on Ce
- Page 135 and 136: CIT2011www.citmd.comCIT Hands-on Ce
- Page 137 and 138: CIT2011www.citmd.comPROGRAM FOR CIT
- Page 139 and 140: CIT2011www.citmd.comEXHIBITORS 参
- Page 141: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 145 and 146: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 147 and 148: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 149 and 150: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 151 and 152: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 153 and 154: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 155: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 158 and 159: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 160 and 161: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 162 and 163: CIT2011www.citmd.comEXHIBITORS' DIR
- Page 164 and 165: CIT2011www.citmd.comCIT2011www.citm
- Page 167 and 168: CIT2011www.citmd.comAcknowledgment